FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030406768> ?p ?o ?g. }

• W2030406768 endingPage "434" @default.
• W2030406768 startingPage "425" @default.
• W2030406768 abstract "We have investigated the role of nitric oxide (NO) as mediator of the secondary growth of a traumatic cortical necrosis. For this purpose, a highly standardized focal lesion of the brain was induced in 46 Sprague-Dawley rats by cold injury. Twenty-four hours later - the timepoint of maximal lesion spread - the animals were sacrificed and brains were removed for histomorphometry of the maximal necrosis area and volume. The animals were divided into five experimental groups. Group I received the NO donor L-arginine as i.v. bolus 10 min prior to trauma (300 mg/kg body weight; n = 10) and a second bolus of the same dosage intraperitoneally 1 h after trauma. Group II (n = 10) - serving as control of group I - was infused with an i.v. bolus of 1 mL/kg isotonic saline 10 min prior to and a subsequent bolus i.p. 1 h after trauma. Group III (n = 8) received 100 mg/kg b.w. of the inducible NOS (iNOS) inhibitor aminoguanidine (AG) 1 h before and 8 h after trauma by intraperitoneal route. Group IV was administered with the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine (L-NNA; 100 mg/kg b.w., i.p.; n = 8); group V - the controls of group III and IV - was administered with isotonic saline (1 mL/kg b.w. i.p.; n = 10) 1 h before and 8 h after trauma. In the control group with i.v./i.p. sham treatment (II), the focal lesion led to a cortical necrosis with a maximum area of 3.1 ± 0.3 mm2 and a lesion volume of 5.7 ± 0.5 mm3 at 24 h after trauma. In animals with administration of L-arginine, the focal lesion had a maximum area of 3.1 ± 0.3 mm2 and a volume of 5.3 ± 0.5 mm3. Hence, the NO donor did not affect the secondary growth of necrosis. Animals with i.p. sham treatment (group V) had a maximal lesion area of 3.6 ± 0.2 mm2 and lesion volume of 6.2 ± 0.4 mm3. Administration of aminoguanidine afforded significant attenuation of the lesion growth. Accordingly, the maximal area of necrosis spread only to 2.8 ± 0.2 mm2 with a volume of 4.5 ± 0.5 mm3, respectively, at 24 h after trauma (p < 0.01 vs group V). On the other hand, administration of L-NNA did not influence the maximal lesion area (3.7 ± 0.2 mm2) or lesion volume (6.5 ± 0.5 mm3) evolving at 24 h after trauma. Thus, neither the enhancement of the formation of NO by L-arginine nor gross inhibition of the synthesis of NO by L-NNA did affect the secondary spread of the necrosis from a focal trauma. The marked attenuation of the posttraumatic necrosis growth by the iNOS inhibitor aminoguanidine strongly indicates an important role of iNOS product in this phenomenon. These findings, thus, demonstrate that the expansion of a primary necrotic focal lesion is a secondary process which can be therapeutically inhibited. Thereby, the growth of a focal tissue necrosis from trauma is clearly identified as a manifestation of secondary brain damage. This information is deemed important for the better understanding of the pathophysiology of traumatic brain injury and for the targeted development of specific treatment modalities." @default.
• W2030406768 created "2016-06-24" @default.
• W2030406768 creator A5024572016 @default.
• W2030406768 creator A5050590944 @default.
• W2030406768 creator A5060637371 @default.
• W2030406768 creator A5066625527 @default.
• W2030406768 creator A5072690135 @default.
• W2030406768 date "2001-04-01" @default.
• W2030406768 modified "2023-10-15" @default.
• W2030406768 title "Role of Nitric Oxide in the Secondary Expansion of a Cortical Brain Lesion from Cold Injury" @default.
• W2030406768 cites W1973671786 @default.
• W2030406768 cites W1974633644 @default.
• W2030406768 cites W1975941571 @default.
• W2030406768 cites W1976022762 @default.
• W2030406768 cites W1981023844 @default.
• W2030406768 cites W1992476000 @default.
• W2030406768 cites W1992549311 @default.
• W2030406768 cites W1995379325 @default.
• W2030406768 cites W1996785529 @default.
• W2030406768 cites W2002325164 @default.
• W2030406768 cites W2003260524 @default.
• W2030406768 cites W2003292990 @default.
• W2030406768 cites W2013492677 @default.
• W2030406768 cites W2015463429 @default.
• W2030406768 cites W2019814232 @default.
• W2030406768 cites W2033020058 @default.
• W2030406768 cites W2035262769 @default.
• W2030406768 cites W2036733223 @default.
• W2030406768 cites W2039215563 @default.
• W2030406768 cites W2039462125 @default.
• W2030406768 cites W2045308185 @default.
• W2030406768 cites W2047843548 @default.
• W2030406768 cites W2049005174 @default.
• W2030406768 cites W2062384458 @default.
• W2030406768 cites W2065384002 @default.
• W2030406768 cites W2065546796 @default.
• W2030406768 cites W2067494203 @default.
• W2030406768 cites W2073167767 @default.
• W2030406768 cites W2074187719 @default.
• W2030406768 cites W2085935168 @default.
• W2030406768 cites W2087690555 @default.
• W2030406768 cites W2094116682 @default.
• W2030406768 cites W2114282533 @default.
• W2030406768 cites W2117573289 @default.
• W2030406768 cites W2125582135 @default.
• W2030406768 cites W2162716309 @default.
• W2030406768 cites W2179702494 @default.
• W2030406768 cites W3158470188 @default.
• W2030406768 cites W4229621016 @default.
• W2030406768 doi "https://doi.org/10.1089/089771501750171010" @default.
• W2030406768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11336443" @default.
• W2030406768 hasPublicationYear "2001" @default.
• W2030406768 type Work @default.
• W2030406768 sameAs 2030406768 @default.
• W2030406768 citedByCount "29" @default.
• W2030406768 countsByYear W20304067682012 @default.
• W2030406768 countsByYear W20304067682013 @default.
• W2030406768 countsByYear W20304067682014 @default.
• W2030406768 countsByYear W20304067682015 @default.
• W2030406768 countsByYear W20304067682016 @default.
• W2030406768 countsByYear W20304067682017 @default.
• W2030406768 countsByYear W20304067682022 @default.
• W2030406768 crossrefType "journal-article" @default.
• W2030406768 hasAuthorship W2030406768A5024572016 @default.
• W2030406768 hasAuthorship W2030406768A5050590944 @default.
• W2030406768 hasAuthorship W2030406768A5060637371 @default.
• W2030406768 hasAuthorship W2030406768A5066625527 @default.
• W2030406768 hasAuthorship W2030406768A5072690135 @default.
• W2030406768 hasConcept C118552586 @default.
• W2030406768 hasConcept C126322002 @default.
• W2030406768 hasConcept C134018914 @default.
• W2030406768 hasConcept C142724271 @default.
• W2030406768 hasConcept C185592680 @default.
• W2030406768 hasConcept C2777397205 @default.
• W2030406768 hasConcept C2777468819 @default.
• W2030406768 hasConcept C2777622882 @default.
• W2030406768 hasConcept C2781017439 @default.
• W2030406768 hasConcept C2781156865 @default.
• W2030406768 hasConcept C2910183285 @default.
• W2030406768 hasConcept C42219234 @default.
• W2030406768 hasConcept C43376680 @default.
• W2030406768 hasConcept C503630168 @default.
• W2030406768 hasConcept C515207424 @default.
• W2030406768 hasConcept C519581460 @default.
• W2030406768 hasConcept C55493867 @default.
• W2030406768 hasConcept C71924100 @default.
• W2030406768 hasConceptScore W2030406768C118552586 @default.
• W2030406768 hasConceptScore W2030406768C126322002 @default.
• W2030406768 hasConceptScore W2030406768C134018914 @default.
• W2030406768 hasConceptScore W2030406768C142724271 @default.
• W2030406768 hasConceptScore W2030406768C185592680 @default.
• W2030406768 hasConceptScore W2030406768C2777397205 @default.
• W2030406768 hasConceptScore W2030406768C2777468819 @default.
• W2030406768 hasConceptScore W2030406768C2777622882 @default.
• W2030406768 hasConceptScore W2030406768C2781017439 @default.
• W2030406768 hasConceptScore W2030406768C2781156865 @default.
• W2030406768 hasConceptScore W2030406768C2910183285 @default.
• W2030406768 hasConceptScore W2030406768C42219234 @default.

• next